Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

1.3K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.3K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

6.8K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.8K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

6.6K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

802
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
802
Introduction to Hemostasis01:05

Introduction to Hemostasis

8.5K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
8.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

575
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
575

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Xylosyltransferase-II deficiency rewires innate immune signaling and destabilizes polarization in human macrophages.

Frontiers in immunology·2026
Same author

Intra-host viral population dynamics during acute hepatitis E virus infection.

mBio·2026
Same author

The Value of Hepatitis E Screening Sensitivity: Lookback Investigation in German Blood Donors.

Viruses·2026
Same author

The Impact of Maternal Obesity and Diabetes on the Development of Congenital Heart Defects (CHDs) in Offspring: A Narrative Review.

Metabolites·2026
Same author

Acquired Factor XIII Deficiency in Critical Care: Registry-Based Analysis of Features, Symptoms and Risk Factors.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
Same author

DNAM-1 mediates NK-cell activation and host-pathogen interaction via direct binding to fungal cell wall proteases.

Communications biology·2026

Related Experiment Video

Updated: Aug 7, 2025

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

667

Immature platelets in COVID-19.

Monika Wolny1, Marcus Dittrich2, Cornelius Knabbe1

  • 1Institut für Laboratoriums- und Transfusionsmedizin, Herz- und Diabeteszentrum NRW, Universitätsklinik der Ruhr-Universität Bochum, Bad Oeynhausen, Deutschland.

Platelets
|March 8, 2023
PubMed
Summary

Severe COVID-19 patients exhibit lower platelet counts and elevated immature platelet fractions (IPF). This indicates impaired platelet production and potential links to disease severity and mortality in coronavirus disease 2019.

Keywords:
COVID-19ECMOimmature platelet fractionplateletsreticulated platelets

More Related Videos

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

19.8K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

555

Related Experiment Videos

Last Updated: Aug 7, 2025

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

667
Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

19.8K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

555

Area of Science:

  • Hematology
  • Immunology
  • Infectious Diseases

Background:

  • Platelets are crucial for immune responses.
  • Severe COVID-19 is associated with coagulation abnormalities, including thrombocytopenia and increased immature platelets.
  • Immature platelet fraction (IPF) reflects platelet production and turnover.

Purpose of the Study:

  • To investigate daily changes in platelet count and IPF in hospitalized COVID-19 patients over 40 days.
  • To analyze platelet function in relation to disease severity and oxygenation requirements.
  • To correlate platelet parameters with patient outcomes, including mortality.

Main Methods:

  • Daily monitoring of platelet count and IPF in hospitalized COVID-19 patients with varying oxygenation needs.
  • Assessment of platelet function.
  • Analysis of platelet parameters stratified by disease severity (mild, moderate, severe) and patient outcome (survival, death).

Main Results:

  • Patients with the most severe COVID-19 (intubation and ECMO) had significantly lower platelet counts (111.5 x 10^6/mL) compared to mild (203.5 x 10^6/mL) and moderate (208.0 x 10^6/mL) cases.
  • Elevated IPF (10.9%) was observed, suggesting increased platelet production.
  • Reduced platelet function was noted in COVID-19 patients.
  • Deceased patients showed significantly lower platelet counts (97.3 x 10^6/mL) and higher IPF (12.2%) compared to survivors.

Conclusions:

  • Severe COVID-19 is characterized by significantly reduced platelet counts and increased IPF.
  • Platelet count and IPF levels are associated with COVID-19 severity and mortality.
  • These findings highlight the role of platelet dysregulation in severe coronavirus disease 2019 pathogenesis.